Peringatan Keamanan

Adverse effects of oral sympathomimetics, such as Nylidrin, are common. The most frequent effects are hypertension, palpitations, nausea, anxiety, mydriasis, and restlessness/agitation L2286.

Large overdoses and severe toxicity may lead to seizures, hallucinations, agitated delirium, and tachydysrhythmias including
supraventricular tachycardia and ventricular tachycardia. Vasospasm can lead to myocardial ischemia focal cerebrovascular deficits. Severe hypertension may also result in intracranial hemorrhage or renal insufficiency. Reflex bradycardia because of significant hypertension is possible. Prolonged agitation can lead to rhabdomyolysis and hyperthermia L2286.

Nylidrin

DB06152

small molecule approved

Deskripsi

Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment L2279.

Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and certain types of ulcers). This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. This effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers L2283.

FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. Therefore, the FDA has withdrawn nylidrin from the U.S. market L2286.

Struktur Molekul 2D

Berat 299.414
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Duration of action is 10h [L2286].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Readily absorbed from the gastrointestinal tract L2279.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1205 Data
Ceritinib Nylidrin may increase the bradycardic activities of Ceritinib.
Ivabradine Nylidrin may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Nylidrin.
Reserpine Nylidrin may decrease the antihypertensive activities of Reserpine.
Remikiren Nylidrin may decrease the antihypertensive activities of Remikiren.
Torasemide Nylidrin may decrease the antihypertensive activities of Torasemide.
Chlorthalidone Nylidrin may decrease the antihypertensive activities of Chlorthalidone.
Minoxidil Nylidrin may decrease the antihypertensive activities of Minoxidil.
Treprostinil Nylidrin may decrease the antihypertensive activities of Treprostinil.
Metolazone Nylidrin may decrease the antihypertensive activities of Metolazone.
Cyclothiazide Nylidrin may decrease the antihypertensive activities of Cyclothiazide.
Candoxatril Nylidrin may decrease the antihypertensive activities of Candoxatril.
Mecamylamine Nylidrin may decrease the antihypertensive activities of Mecamylamine.
Metyrosine Nylidrin may decrease the antihypertensive activities of Metyrosine.
Hydroflumethiazide Nylidrin may decrease the antihypertensive activities of Hydroflumethiazide.
Cryptenamine Nylidrin may decrease the antihypertensive activities of Cryptenamine.
Fenoldopam Nylidrin may decrease the antihypertensive activities of Fenoldopam.
Chlorothiazide Nylidrin may decrease the antihypertensive activities of Chlorothiazide.
Hydrochlorothiazide Nylidrin may decrease the antihypertensive activities of Hydrochlorothiazide.
Trichlormethiazide Nylidrin may decrease the antihypertensive activities of Trichlormethiazide.
Deserpidine Nylidrin may decrease the antihypertensive activities of Deserpidine.
Pentolinium Nylidrin may decrease the antihypertensive activities of Pentolinium.
Trimethaphan Nylidrin may decrease the antihypertensive activities of Trimethaphan.
Diazoxide Nylidrin may decrease the antihypertensive activities of Diazoxide.
Epoprostenol Nylidrin may decrease the antihypertensive activities of Epoprostenol.
Polythiazide Nylidrin may decrease the antihypertensive activities of Polythiazide.
Tienilic acid Nylidrin may decrease the antihypertensive activities of Tienilic acid.
Debrisoquine Nylidrin may decrease the antihypertensive activities of Debrisoquine.
Diethylnorspermine Nylidrin may decrease the antihypertensive activities of Diethylnorspermine.
Hexamethonium Nylidrin may decrease the antihypertensive activities of Hexamethonium.
Rauwolfia serpentina root Nylidrin may decrease the antihypertensive activities of Rauwolfia serpentina root.
Angiotensin 1-7 Nylidrin may decrease the antihypertensive activities of Angiotensin 1-7.
BQ-123 Nylidrin may decrease the antihypertensive activities of BQ-123.
Dihydralazine Nylidrin may decrease the antihypertensive activities of Dihydralazine.
Guanoxan Nylidrin may decrease the antihypertensive activities of Guanoxan.
Vincamine Nylidrin may decrease the antihypertensive activities of Vincamine.
Linsidomine Nylidrin may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Nylidrin may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Nylidrin may decrease the antihypertensive activities of Tolonidine.
Endralazine Nylidrin may decrease the antihypertensive activities of Endralazine.
Cadralazine Nylidrin may decrease the antihypertensive activities of Cadralazine.
Cyclopenthiazide Nylidrin may decrease the antihypertensive activities of Cyclopenthiazide.
Bietaserpine Nylidrin may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Nylidrin may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Nylidrin may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Nylidrin may decrease the antihypertensive activities of Guanoclor.
Muzolimine Nylidrin may decrease the antihypertensive activities of Muzolimine.
Xipamide Nylidrin may decrease the antihypertensive activities of Xipamide.
Tocopherylquinone Nylidrin may decrease the antihypertensive activities of Tocopherylquinone.
Furosemide Nylidrin may decrease the antihypertensive activities of Furosemide.
Bosentan Nylidrin may decrease the antihypertensive activities of Bosentan.
Indapamide Nylidrin may decrease the antihypertensive activities of Indapamide.
Tadalafil Nylidrin may decrease the antihypertensive activities of Tadalafil.
Guanfacine Nylidrin may decrease the antihypertensive activities of Guanfacine.
Hydralazine Nylidrin may decrease the antihypertensive activities of Hydralazine.
Sitaxentan Nylidrin may decrease the antihypertensive activities of Sitaxentan.
Ambrisentan Nylidrin may decrease the antihypertensive activities of Ambrisentan.
Pinacidil Nylidrin may decrease the antihypertensive activities of Pinacidil.
Riociguat Nylidrin may decrease the antihypertensive activities of Riociguat.
Macitentan Nylidrin may decrease the antihypertensive activities of Macitentan.
Selexipag Nylidrin may decrease the antihypertensive activities of Selexipag.
Levamlodipine Nylidrin may decrease the antihypertensive activities of Levamlodipine.
Buthiazide Nylidrin may decrease the antihypertensive activities of Buthiazide.
Atomoxetine The risk or severity of hypertension can be increased when Atomoxetine is combined with Nylidrin.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with Nylidrin.
Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Nylidrin.
Bethanidine Nylidrin may decrease the antihypertensive activities of Bethanidine.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with Nylidrin.
Etomidate The risk or severity of hypertension can be increased when Etomidate is combined with Nylidrin.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with Nylidrin.
Methylphenidate The risk or severity of hypertension can be increased when Methylphenidate is combined with Nylidrin.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Nylidrin.
Furazolidone The risk or severity of hypertension can be increased when Furazolidone is combined with Nylidrin.
Guanabenz Nylidrin may decrease the antihypertensive activities of Guanabenz.
Sumatriptan The risk or severity of hypertension can be increased when Sumatriptan is combined with Nylidrin.
Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with Nylidrin.
Minaprine The risk or severity of hypertension can be increased when Minaprine is combined with Nylidrin.
Propofol The risk or severity of hypertension can be increased when Propofol is combined with Nylidrin.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with Nylidrin.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with Nylidrin.
Rizatriptan The risk or severity of hypertension can be increased when Rizatriptan is combined with Nylidrin.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with Nylidrin.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with Nylidrin.
Moclobemide The risk or severity of hypertension can be increased when Moclobemide is combined with Nylidrin.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with Nylidrin.
Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with Nylidrin.
Arformoterol The risk or severity of hypertension can be increased when Arformoterol is combined with Nylidrin.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with Nylidrin.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with Nylidrin.
Rasagiline The risk or severity of hypertension can be increased when Rasagiline is combined with Nylidrin.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with Nylidrin.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Nylidrin.
Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with Nylidrin.
Pargyline Nylidrin may decrease the antihypertensive activities of Pargyline.
Epicaptopril The risk or severity of hypertension can be increased when Epicaptopril is combined with Nylidrin.
Taxifolin The risk or severity of hypertension can be increased when Taxifolin is combined with Nylidrin.
Clorgiline The risk or severity of hypertension can be increased when Clorgiline is combined with Nylidrin.
1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Nylidrin.
Iproniazid The risk or severity of hypertension can be increased when Iproniazid is combined with Nylidrin.
Nialamide The risk or severity of hypertension can be increased when Nialamide is combined with Nylidrin.

Target Protein

Interferon alpha/beta receptor 2 IFNAR2
Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I

Referensi & Sumber

Artikel (PubMed)
  • PMID: 2883089
    Niemeyer G, Cottier D, Resch H: Effects of buphenine (nylidrin) on the perfused mammalian eye. Graefes Arch Clin Exp Ophthalmol. 1987;225(1):33-8.
  • PMID: 1094787
    Castren O, Gummerus M, Saarikoski S: Treatment of imminent premature labour. Acta Obstet Gynecol Scand. 1975;54(2):95-100.
  • PMID: 3049092
    Walter U, Waldmann R, Nieberding M: Intracellular mechanism of action of vasodilators. Eur Heart J. 1988 Jun;9 Suppl H:1-6.

Contoh Produk & Brand

Produk: 3 • International brands: 2
Produk
  • Arlidin
    Tablet • 6 mg • Oral • Canada • Approved
  • Arlidin Forte Tab 12mg
    Tablet • 12 mg • Oral • Canada • Approved
  • PMS-nylidrin Tab 6mg
    Tablet • 6 mg • Oral • Canada • Generic • Approved
International Brands
  • Arbid
  • Arlidin

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul